The co-expressing status of OCT4, SOX2, and NANOG in tumor tissues was also evaluated; and there were 2 (11%) patients with no marker expressed, 5 (28%) patients with only one marker expressed, and 8 (44%) patients with two markers significantly expressed [the expression groups included 1) the OCT4high and SOX2high group (n = 6, 33%); 2) the OCT4high and NANOGhigh group (n = 1, 6%); and 3) the SOX2high and NANOGhigh group (n = 1, 6%)]. The gene discussed is SOX2; the disease is neoplasm.